Cue Biopharma
CUE
90 hedge funds and large institutions have $216M invested in Cue Biopharma in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 10 closing their positions.
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 89 → 90 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.09% less ownership
Funds ownership: 2.06% → 1.97% (-0.09%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
6% less capital invested
Capital invested by funds: $230M → $216M (-$13.2M)
52% less call options, than puts
Call options by funds: $814K | Put options by funds: $1.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$6M |
| 2 |
6CM
683 Capital Management
New York
|
+$4.74M |
| 3 |
Millennium Management
New York
|
+$1.95M |
| 4 |
Morgan Stanley
New York
|
+$1.4M |
| 5 |
BL
Bleichroeder LP
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$13.7M |
| 2 |
Goldman Sachs
New York
|
-$2.68M |
| 3 |
Two Sigma Investments
New York
|
-$1.59M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.35M |
| 5 |
BlackRock
New York
|
-$1.28M |
CUE Hedge Fund Activity: Q2 2021 in Review
90 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2021, worth a combined $216M — down 5.7% from $230M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CUE positions and 10 closed out — a net gain of 1 holder — while 29 added to existing stakes and 31 trimmed.
The largest buyer was Woodline Partners, adding an estimated $6M. The largest seller was Corriente Advisors, cutting an estimated $13.7M.
- 90 institutional investors held Cue Biopharma (CUE) as of Q2 2021, up from 89 in Q1 2021.
- Funds reported $216M of Cue Biopharma stock for Q2 2021, down 5.7% quarter-over-quarter.
- 11 funds opened new Cue Biopharma positions in Q2 2021 and 10 closed out, a net change of +1 holder.
- The largest Cue Biopharma buyer in Q2 2021 was Woodline Partners, an estimated $6M added.
- The largest Cue Biopharma seller in Q2 2021 was Corriente Advisors, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2021.